Physicians

Department / Division
Pediatrics / Pediatrics-Primary Care

Address
DUMC 3675
Durham, NC 27710

Appointment Telephone
919-620-5333

Office Telephone
919-620-5374

Fax Telephone
919-471-3820

Training

• MD, University of Maryland School of Medicine, 1983

Residency

• Pediatrics, University of Maryland Medical Center, 1983-1986

Fellowship

• Pediatric Infectious Diseases, Duke University Medical Center, 1987-1990

Other Training

• MPH, University of North Carolina–Chapel Hill, 1992

Clinical Interests
General pediatrics, childhood and adult immunizations

Research Interests
Dr. Emmanuel (Chip) Walter is Director of the Duke Translational Medicine Institute Clinical Vaccine Unit and he is Associate Director of the Primary Care Research Consortium at the Duke Clinical Research Institute.

Vaccine research:

1) Clinical trials (vaccines for biodefense, pandemic and seasonal influenza virus vaccines, investigational respiratory virus vaccines, rotavirus vaccine, human papilloma virus vaccine, conjugate pneumococcal vaccine, meningococcal vaccines, combination vaccines)

2) Vaccine utilization (influenza vaccination of special populations, adolescent immunization)

Epidemiologic studies:

National Children's Study

Industry Relationships and Collaborations (What's this?)

This faculty member has no reported relationships with industry.

Representative Publications
Chen, WH; Winokur, PL; Edwards, KM; Jackson, LA; Wald, A; Walter, EB; Noah, DL; Wolff, M; Kotloff, KL; Pandemic H1N1 Vaccine Adult Study Group. Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. Vaccine. 2012;30:4240-4248. (2012) Abstract

Frenck, RW; Belshe, R; Brady, RC; Winokur, PL; Campbell, JD; Treanor, J; Hay, CM; Dekker, CL; Walter, EB; Cate, TR; Edwards, KM; Hill, H; Wolff, M; Leduc, T; Tornieporth, N. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults. Vaccine. 2011;29:5666-5674. (2011) Abstract

Hauber, AB; Itzler, R; Johnson, FR; Mohamed, AF; González, JM; Cook, JR; Walter, EB. Healthy-days time equivalents for outcomes of acute rotavirus infections. Vaccine. 2011;29:8086-8093. (2011) Abstract

Moody, MA; Zhang, R; Walter, EB; Woods, CW; Ginsburg, GS; McClain, MT; Denny, TN; Chen, X; Munshaw, S; Marshall, DJ; Whitesides, JF; Drinker, MS; Amos, JD; Gurley, TC; Eudailey, JA; Foulger, A; DeRosa, KR; Parks, R; Meyerhoff, RR; Yu, JS; Kozink, DM; Barefoot, BE; Ramsburg, EA; Khurana, S; Golding, H; Vandergrift, NA; Alam, SM; Tomaras, GD; Kepler, TB; Kelsoe, G; Liao, HX; Haynes, BF. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One. 2011;6:e25797. (2011) Abstract

Tan, W; Viera, AJ; Rowe-West, B; Grimshaw, A; Quinn, B; Walter, EB. The HPV vaccine: are dosing recommendations being followed?. Vaccine. 2011;29:2548-2554. (2011) Abstract

Walter, EB; Dole, N; Siega-Riz, AM; Entwisle, B. The National Children's Study in North Carolina: a study of the effect of the environment on children's health, growth, and development. North Carolina Medical Journal. 2011;72:160-164. (2011) Abstract

Whittle, JR; Zhang, R; Khurana, S; King, LR; Manischewitz, J; Golding, H; Dormitzer, PR; Haynes, BF; Walter, EB; Moody, MA; Kepler, TB; Liao, HX; Harrison, SC. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proceedings of the National Academy of Sciences of USA. 2011;108:14216-14221. (2011) Abstract

Englund, JA; Walter, E; Black, S; Blatter, M; Nyberg, J; Ruben, FL; Decker, MD; GRC28 Study Team. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. Pediatric Infectious Disease Journal. 2010;29:105-110. (2010) Abstract

Halperin, SA; Gupta, A; Jeanfreau, R; Klein, NP; Reisinger, K; Walter, E; Bedell, L; Gill, C; Dull, PM. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine. 2010;28:7865-7872. (2010) Abstract

Mast, TC; Walter, EB; Bulotsky, M; Khawaja, SS; DiStefano, DJ; Sandquist, MK; Straus, WL; Staat, MA. Burden of childhood rotavirus disease on health systems in the United States. Pediatric Infectious Disease Journal. 2010;29:e19-e25. (2010) Abstract

Walter, EB; Allred, NJ; Swamy, GK; Hellkamp, AS; Dolor, RJ. Influenza vaccination of household contacts of newborns: a hospital-based strategy to increase vaccination rates. Infection Control and Hospital Epidemiology. 2010;31:1070-1073. (2010) Abstract

Walter, EB; Rajagopal, S; Zhu, Y; Neuzil, KM; Fairchok, MP; Englund, JA. Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally?. Vaccine. 2010;28:4376-4383. (2010) Abstract

Liao, HX; Levesque, MC; Nagel, A; Dixon, A; Zhang, R; Walter, E; Parks, R; Whitesides, J; Marshall, DJ; Hwang, KK; Yang, Y; Chen, X; Gao, F; Munshaw, S; Kepler, TB; Denny, T; Moody, MA; Haynes, BF. High-throughput isolation of immunoglobulin genes from single human B cells and expression as monoclonal antibodies. Journal of Virological Methods. 2009;158:171-179. (2009) Abstract

Mast, TC; DeMuro-Mercon, C; Kelly, CM; Floyd, LE; Walter, EB. The impact of rotavirus gastroenteritis on the family. BMC Pediatrics. 2009;9:11. (2009) Abstract

Walter, EB; Allred, N; Rowe-West, B; Chmielewski, K; Kretsinger, K; Dolor, RJ. Cocooning infants: Tdap immunization for new parents in the pediatric office. Academic Pediatrics. 2009;9:344-347. (2009) Abstract

Walter, EB; Englund, JA; Blatter, M; Nyberg, J; Ruben, FL; Decker, MD; GRC27 Study Team. Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study. Pediatric Infectious Disease Journal. 2009;28:1099-1104. (2009) Abstract

Keitel, WA; Campbell, JD; Treanor, JJ; Walter, EB; Patel, SM; He, F; Noah, DL; Hill, H. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. Journal of Infectious Diseases. 2008;198:1309-1316. (2008) Abstract

Talbot, HK; Keitel, W; Cate, TR; Treanor, J; Campbell, J; Brady, RC; Graham, I; Dekker, CL; Ho, D; Winokur, P; Walter, E; Bennet, J; Formica, N; Hartel, G; Skeljo, M; Edwards, KM. Immunogenicity, safety and consistency of new trivalent inactivated influenza vaccine. Vaccine. 2008;26:4057-4061. (2008) Abstract

Walter, EB; Snyder, MA; Clements, DA; Katz, SL. Large injection site reactions after a second dose of varicella vaccine. Pediatric Infectious Disease Journal. 2008;27:757-759. (2008) Abstract

Englund, JA; Walter, EB; Gbadebo, A; Monto, AS; Zhu, Y; Neuzil, KM. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics. 2006;118:e579-e585. (2006) Abstract

Guerra, FA; Gress, J; Werzberger, A; Reisinger, K; Walter, E; Lakkis, H; Grosso, AD; Welebob, C; Kuter, BJ; Pediatric Study Group for VAQTA. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatric Infectious Disease Journal. 2006;25:912-919. (2006) Abstract

Walter, EB; Neuzil, KM; Zhu, Y; Fairchok, MP; Gagliano, ME; Monto, AS; Englund, JA. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?. Pediatrics. 2006;118:e570-e578. (2006) Abstract

Englund, JA; Walter, EB; Fairchok, MP; Monto, AS; Neuzil, KM. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. Pediatrics. 2005;115:1039-1047. (2005) Abstract

Clark, HF; Burke, CJ; Volkin, DB; Offit, P; Ward, RL; Bresee, JS; Dennehy, P; Gooch, WM; Malacaman, E; Matson, D; Walter, E; Watson, B; Krah, DL; Dallas, MJ; Schödel, F; Kaplan, KM; Heaton, P. Safety, immunogenicity and efficacy in healthy infants of G1 and G2 human reassortant rotavirus vaccine in a new stabilizer/buffer liquid formulation. Pediatric Infectious Disease Journal. 2003;22:914-920. (2003) Abstract

Clements, DA; Zaref, JI; Bland, CL; Walter, EB; Coplan, PM. Partial uptake of varicella vaccine and the epidemiological effect on varicella disease in 11 day-care centers in North Carolina. Archives of Pediatrics and Adolescent Medicine. 2001;155:455-461. (2001) Abstract

Clements, DA; Moreira, SP; Coplan, PM; Bland, CL; Walter, EB. Postlicensure study of varicella vaccine effectiveness in a day-care setting. Pediatric Infectious Disease Journal. 1999;18:1047-1050. (1999) Abstract

Walter, EB; Hornick, RB; Poland, GA; Tucker, R; Bland, CL; Clements, DA; Rhamstine, CC; Jacobson, RM; Brown, L; Gress, JO; Harris, KE; Wiens, BL; Nalin, DR. Concurrent administration of inactivated hepatitis A vaccine with immune globulin in healthy adults. Vaccine. 1999;17:1468-1473. (1999) Abstract

Clements, DA; Armstrong, CB; Ursano, AM; Moggio, MM; Walter, EB; Wilfert, CM. Over five-year follow-up of Oka/Merck varicella vaccine recipients in 465 infants and adolescents. Pediatric Infectious Disease Journal. 1995;14:874-879. (1995) Abstract

Clements, DA; Langdon, L; Bland, C; Walter, E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Archives of Pediatrics and Adolescent Medicine. 1995;149:1113-1117. (1995) Abstract